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Introduction
Despite ambitious plans proposed by the Roll Back Malaria 
(RBM) Partnership in its Global Malaria Action Plan,1 the 
relation between malaria and poverty means that most 
malaria-endemic countries will be unable to ﬁ nance 
national, regional, or worldwide control ambitions un-
assisted. Achievement of eﬀ ective levels of malaria control 
within the next 10–20 years will depend on sustained 
international funding to meet the needs of resource-poor 
endemic countries. Since 2002, the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (Global Fund);2 the World 
Bank Booster Program;3 the President’s Malaria Initiative;4 
and other bilateral and multilateral agency support to 
countries has increased investment in malaria control to 
meet targets outlined as part of Millennium Development 
Goal (MDG)5 (to reduce infant and child mortality by two-
thirds) and MDG 6c (to increase coverage of eﬀ ective 
interventions against malaria by 2015).4
At face value, ﬁ nancing by the international donor 
community has exceeded the expectations set when RBM 
was launched more than 10 years ago. However, increasing 
funding that remains below that needed in high-risk high-
population poor countries will not achieve worldwide 
target reductions in disease incidence. To deﬁ ne whether 
countries will reach their MDG targets it is important to 
understand, not just aggregate funding, but the equity and 
adequacy of this funding so that investments to reach the 
MDGs are targeted appropriately.
During previous analyses of funding commitments to 
malaria control we assembled data on populations at risk 
of stable Plasmodium falciparum transmission only;6 it 
was not possible at that time to construct an informed 
basis of the worldwide extent of stable Plasmodium vivax 
transmission. The substantial worldwide public-health 
consequences of P vivax are often ignored,7 thus 
diminishing the worldwide deﬁ nitions of funding needs 
and limiting the value of between-country comparisons 
of appropriate funding levels for malaria control. Most 
countries outside sub-Saharan Africa develop strategies 
and needs based on the prevention of both P falciparum 
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Summary
Background Financing for malaria control has increased as part of international commitments to achieve the 
Millennium Development Goals (MDGs). We aimed to identify the unmet ﬁ nancial needs that would be biologically and 
economically equitable and would increase the chances of reaching worldwide malaria-control ambitions.
Methods Populations at risk of stable Plasmodium falciparum or Plasmodium vivax transmission were calculated for 
2007 and 2009 for 93 malaria-endemic countries to measure biological need. National per-person gross domestic product 
(GDP) was used to deﬁ ne economic need. An analysis of external donor assistance for malaria control was done for the 
period 2002–09 to compute overall and annualised per-person at-risk-funding commitments. Annualised malaria donor 
assistance was compared with independent predictions of funding needed to reach international targets of 80% coverage 
of best practices in case-management and eﬀ ective disease prevention. Countries were ranked in relation to biological, 
economic, and unmet needs to examine equity and adequacy of support by 2010.
Findings International ﬁ nancing for malaria control has increased by 166% (from $0·73 billion to $1·94 billion) 
since 2007 and is broadly consistent with biological needs. African countries have become major recipients of external 
assistance; however, countries where P vivax continues to pose threats to control ambitions are not as well funded. 
21 countries have reached adequate assistance to provide a comprehensive suite of interventions by 2009, including 
12 countries in Africa. However, this assistance was inadequate for 50 countries representing 61% of the worldwide 
population at risk of malaria—including ten countries in Africa and ﬁ ve in Asia that coincidentally are some of the 
poorest countries. Approval of donor funding for malaria control does not correlate with GDP.
Interpretation Funding for malaria control worldwide is 60% lower than the US$4·9 billion needed for comprehensive 
control in 2010; this includes funding shortfalls for a wide range of countries with diﬀ erent numbers of people at risk 
and diﬀ erent levels of domestic income. More eﬃ  cient targeting of ﬁ nancial resources against biological need and 
national income should create a more equitable investment portfolio that with increased commitments will guarantee 
sustained ﬁ nancing of control in countries most at risk and least able to support themselves.
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and P vivax with screening, diagnosis, and treatment 
strategies that are parasite speciﬁ c. The geographical 
distribution of the two parasites overlaps widely, although 
there are notable exceptions including 12 malaria-
endemic countries where transmission is exclusively 
limited to P vivax, and others in which P falciparum exists 
only in constrained foci. We use the recently published 
mapped worldwide distribution of P vivax8 in combination 
with the distribution of P falciparum transmission9 and 
combine these data with the most recent ﬁ nancing 
information to improve, update, and review the 
international funding commitments by the end of 2009. 
We use this framework to identify the unmet ﬁ nancial 
needs that would be biologically and economically 
equitable and would increase the chances of achieving 
worldwide malaria-control ambitions.1,5
Methods
Assessment of biological equity 
We included all malaria-endemic countries for which 
there was suﬃ  cient evidence of contemporary 
transmission of either P falciparum or P vivax. Eight 
countries that had small residual foci of possible 
transmission or were close to elimination were excluded 
(Mayotte, Jamaica, Mauritius, Algeria, Egypt, Reunion, 
Oman, and Uzbekistan). We did not include a further 
four countries (Cape Verde, El Salvador, Iraq, and 
Kyrgyzstan) because these were subsequently identiﬁ ed 
as having no populations at risk of either P vivax or 
P falciparum stable transmission. The geographical extent 
of P vivax transmission in Africa and its relation with the 
Duﬀ y-negative phenotype (Fya–b–) on the surface of red 
blood cells remain uncertain. We regard P vivax risk 
countries in Africa as Sudan, Somalia, Djibouti, Ethiopia, 
Eritrea, Comoros, and Madagascar.
We deﬁ ned populations within each of the remaining 
93 countries as either malaria free, at risk of unstable 
transmission, or at risk of stable transmission of 
P falciparum9,10 or P vivax.8 Within each country the 
absence of transmission was deﬁ ned after a 
comprehensive review of international travel advisories, 
subnational case-reporting averaged over several years, 
and biological masks developed on the basis of 
temperature-limiting eﬀ ects of parasite development 
within the dominant country-speciﬁ c mosquito-vector 
populations combined with vector longevity speciﬁ c to 
P falciparum9 and P vivax.8 Unstable transmission refers 
to areas where national reports of incident cases total 
less than one P vivax or P falciparum case per 
10 000 population in an average recent year or where 
the eﬀ ects of extreme aridity would not support vector 
survival but where there might be risks around man-
made breeding sites. Areas able to support stable 
transmission represent health-reporting districts within 
a national border that have a documented case incidence 
of at least 1 case per 10 000 population per year and are 
biologically suited to trans mission by local vector 
populations.8,9 These medical intelligence, routine 
reporting, and biological threshold data were 
incorporated as 1×1 km resolution spatial-grid surfaces 
and combined by use of ArcGIS 9.3 to generate separate 
maps for P falciparum and P vivax, to identify areas of 
risk-free, unstable, and stable transmission for each 
parasite. These maps were then combined to produce a 
single joint-risk map that delineated those areas at 
stable risk of either parasite.
The Global Rural Urban Mapping Project beta version 
provides gridded population counts and population 
density estimates for the years 1990, 1995, and 2000, 
both adjusted and unadjusted to the UN’s national 
population estimates.11 Adjusted population counts for 
the year 2000 were projected to 2007 and 2009 by 
applying national, medium-variant, urban, and rural-
speciﬁ c growth rates by country,12 resulting in 
population-count surfaces for 2007 and 2009 at about 1 
× 1 km spatial resolution. These surfaces were overlaid 
with the joint-risk map to deﬁ ne the combined 
population at risk in each country of either stable 
P vivax or stable P falciparum transmission (PfPv PAR). 
We did not use PfPv PAR of unstable transmission 
where the highly focal epidemiology of malaria presents 
challenges for accurate distinction of small from 
true zero risk of disease.9 Moreover, where risk is 
exceptionally low, decisions on the appropriate targets 
and sets of evidence-based interventions remain 
uncertain. However, our deﬁ nition of stable 
transmission encompasses a large range of transmission 
intensities between and within countries9,10 and 
populations exposed to parasites in this endemicity 
range are most likely to beneﬁ t from tailored 
combinations of widely promoted treatment and 
prevention strategies.
Deﬁ nition of international funding commitments
We have assembled details on malaria-speciﬁ c external 
donor assistance to the 93 endemic countries since 2002 
(webappendix pp 1–3). Data included the dates, amounts, 
and sources of funding obtained from online sources,2–4 
previous reviews,6 the Creditor Reporting System (CRS) 
of oﬃ  cial development assistance maintained by the 
Organisation for Economic Co-operation and 
Development,13 and country-level assessments by RBM.14 
Committed funding was indentiﬁ ed up to the end 
of 2009, including the ninth round of funding by the 
Global Fund and the President’s Malaria Initiative 
commitments for the ﬁ nancial year 2010. The CRS 
database did not include funding awards for 2009 and 
showed incomplete data for periods before 2007. 
Information between sources was reconciled to remove 
reporting duplications. Awards covered periods from 
2002 to 2015; if they were sequential or renewable the 
ﬁ rst award date was used to deﬁ ne the entire donor-
commitment period. The duration of assistance was 
computed in months and annualised to an average yearly 
See Online for webappendix
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commitment across the period of data assembly. The 
annualised funding commitment therefore represents a 
cumulative average year, allowing analysis of average 
yearly funding available to deliver commodities, services, 
training, and monitoring of each country’s national 
malaria-control plan since 2002. Similar data sources and 
methods were used in previous analyses of funding 
commitments,6 and these data have been reassembled 
for comparison purposes to cover all P vivax and 
P falciparum endemic countries representing funding 
commitments up to the end of 2007, corresponding to 
the Global Fund awards including the seventh round and 
before the expanded President’s Malaria Initiative 
programme in Africa. Summed commitments across all 
donors for the period up to 2007 and 2009 were used to 
compute the average yearly per-person external funding 
for these two periods (webappendix pp 1–3). The 
assemblies do not assess disbursed funding, arguably a 
more precise measure of ﬁ nancing available to deliver 
interventions, because this was incomplete for the 
periods under consideration or unobtainable for many 
bilateral sources.
Assessment of funding adequacy
Kiszewski and colleagues15 developed a model frame-
work to estimate the commodity requirements 
(pharma ceuticals, diagnostics, insecticides, and treated 
nets) and supporting infrastructure needed to meet 
Figure 1: Per-person at-risk donor assistance (US$) by 2007 and 2009 across 93 malaria-endemic countries where stable transmission exists
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eﬀ ective malaria control for 81 countries yearly between 
2006 and 2015. This framework represents the most 
comprehensive review of component costs to reach 
80% coverage of best practices in case-management 
and eﬀ ective disease prevention. The investigators 
included diﬀ erent sets of interventions and structured 
their analysis to show diﬀ erences between sub-Saharan 
Africa and Asia, Oceania, and the Americas. Optimistic 
targeted disease-reduction scenarios incorporated 
changing demands on case management as disease 
prevention reached appropriate levels of coverage. The 
eﬀ ect of single-intervention approaches was reviewed 
to provide an optimistic scenario that achieved 
substantive reductions in morbidity and mortality 
by 2015 and coincidentally included a reduced cost of 
case management as disease prevention reached high 
coverage levels. These anticipated optimistic health 
eﬀ ects have been used here as in subsequent reviews16,17 
because they have been empirically conﬁ rmed at 
selected sites where projected coverage levels have 
already,18 or almost,19,20 been reached. The predicted 
annualised per-person “needs” values were extracted 
under the optimistic projection scenario for the 
year 2010 and used to compare unmet needs for our 
deﬁ nitions of populations at risk of stable P vivax or 
P falciparum transmission in 2009. For the 15 countries 
where no projected needs were available we have taken 
the median yearly per-person estimate of need from 
countries within the region and applied to those 
without information (webappendix pp 1–3).
Assessment of funding equity
The examination of ﬁ nancial needs for expanded malaria 
control must include actual and potential national 
support from domestic sources. We did not include 
funding commitments derived from national public 
expenditure14 because these are incomplete (no records 
for more than 35 countries) or, where data are available, 
diﬃ  cult to interpret. For example, in 2008, the Burundian 
Government was reported to have committed 
US$46 million to malaria control activities and the 
Malawian Government $24 million, compared with 
$35 500 by the Kenyan Government in the same year. 
These disparities probably show how broad health-sector 
bilateral assistance is accounted for rather than showing 
real diﬀ erences in government expenditure on malaria.
Eligibility for development assistance is often based on 
gross domestic product (GDP) or gross national 
income (GNI).21,22 To examine priorities for future 
ﬁ nancing of malaria control we ranked countries 
according to the per-person GDP deﬁ ned by the 
World Bank to represent a country’s overall economic 
wealth (webappendix pp 1–3).23 Additionally, we have 
recalculated needs and examined priority funding 
accounting for some approximation to eligibility provided 
by the Development Assistance Committee of the OECD 
of upper-middle-income countries21 and countries facing 
unsustainable debt classiﬁ ed by the International 
Monetary Fund as heavily indebted poor countries.24
Results
In 2007, 16 malaria-endemic countries had not received 
any international assistance for malaria control (ﬁ gure 1). 
By 2009, Azerbaijan, Botswana, Brazil, Congo, and South 
Korea had all received funding from the Global Fund, 
leaving 11 countries with no international assistance for 
malaria control (ﬁ gure 1). These 11 countries represent 
less than 0·9% of about 2 billion people exposed to stable 
P vivax or P falciparum transmission in 2007–09.
By the end of 2009, more than US$9·9 billion had been 
committed by international donor agencies for malaria 
control in 81 countries where populations were exposed 
to stable P vivax or P falciparum transmission: 
75·6% committed by the Global Fund since 2002, 
$0 funding per person $0–1 funding per person $>1–4 funding per person $>4 funding per person
≥$4000 per-person GDP Argentina,* Belize,* Costa Rica,* Mexico,* 
Panama,* Saudi Arabia, South Korea, 
Turkey,* Malaysia,* French Guiana*
Botswana,* Colombia, South 
Africa*
Brazil,* Dominican Republic, Namibia, Venezuela* Iran, Gabon,* 
Equatorial Guinea, 
Suriname*
$≥1000 to <$4000 
per-person GDP
Paraguay Bhutan, Cameroon,† China, 
Ecuador, Guatemala, Honduras,† 
India, Indonesia, Nicaragua,† 
Peru, Philippines, Thailand
Angola, Bolivia,† Congo, Georgia, Guyana, Nigeria, 
Solomon Islands, Sri Lanka, Sudan
Azerbaijan, Swaziland, 
Vanuatu
≥$500 to <$1000 
per-person GDP
·· Chad,† Haiti,† Laos, Pakistan, 
Vietnam, Yemen
Côte d’Ivoire,† Benin,† Cambodia, Comoros, Djibouti, 
Ghana,† Kenya, Mali,† Mauritania,† Senegal,† 
Tajikistan
Zambia,† Papua New 
Guinea, São Tomé and 
Príncipe†
<$500 per-person GDP ·· Bangladesh, Burma, Guinea,† 
Nepal, North Korea
Afghanistan,† Burkina Faso,† Burundi,† Central African 
Republic,† Democratic Republic of the Congo,† Eritrea, 
Ethiopia,† Gambia,† Guinea-Bissau,† Madagascar,† 
Malawi,† Mozambique,† Niger,† Sierra Leone,† 
Somalia, Tanzania,† Timor-Leste, Togo,† Uganda†
Liberia,† Rwanda,† 
Zimbabwe
Currency is US$. GDP=gross domestic product. *Countries that are regarded by the Development Assistance Committee of the Organisation for Economic Co-operation and Development as middle-high income 
countries least eligible for donor assistance. †Countries that are regarded as heavily indebted countries that have received or pending debt cancellation.
Table: Countries according to international funding awarded per person at stable malaria risk per year up to end of 2009 and per-person gross domestic product
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12·8% by the President’s Malaria Initiative since 2004, 
4·9% through the World Bank Booster Program 
since 2006, 1·4% through the US Agency for International 
Development, and an estimated 5·3% provided through 
other bilateral and multilateral agencies. Average 
annualised international donor assistance to malaria-
endemic countries rose by 166% from $0·73 billion by 
the end of 2007 to $1·94 billion by the end of 2009.
Among the 81 endemic countries that have received 
some international assistance for malaria control 
since 2002, 26 (32%) continue to receive less than $1 per 
person at risk in an average year by 2009 (ﬁ gure 1 and 
table). However, there has been substantial improvement 
since 2007 when 47 (61%) of 77 recipient countries were 
funded at this level (ﬁ gure 1). The greatest improvements 
in funding since 2007 have been in Africa, with modest 
changes in the Americas and, with the exception of 
Sri Lanka and Papua New Guinea, almost no change 
across much of southeast Asia (ﬁ gure 1). Overall there 
is a strong correlation between funding provided 
since 2002 and populations at risk of stable transmission 
across the 81 countries that received funding (ﬁ gure 2; 
r=0·76, p<0·001). Although countries with bigger 
populations at risk tend to get more donor assistance, 
there are important anomalies. Five countries 
(Azerbaijan, Suriname, São Tomé and Príncipe, 
Equatorial Guinea, and Swaziland) were in receipt of 
more than $10 per person at risk and all were countries 
with small at-risk populations: 0·05% of the worldwide 
stable-risk population but receiving 0·9% of the yearly 
malaria funding commitment. 13 countries by 
2009 received more than $4 per person at-risk per year 
(ﬁ gure 1), compared with only three countries in 2007 
(ﬁ gure 1); these countries represent 2% of the worldwide 
population at risk of stable malaria transmission 
in 2009, but receive 11·8% of the annualised international 
funding commitment. 37% of people living under stable 
malaria transmission in 2009 were in India, which 
received only $0·03 external development assistance 
per person at risk, and China, which received only 
$0·28, or 2% of total annualised donor funding for 
malaria. Neither country is poor, although large sectors 
of their population live in poverty, and arguably they 
might be seen as able to fund national malaria control 
from domestic resources. We use these examples here 
to illustrate how donor assistance does not always scale 
with populations at risk.
As one might expect, most high per-person 
GDP countries have received no international donor 
assistance, although four have received a yearly average 
of more than $4 per person at risk of stable malaria 
transmission (table). Gabon and Equatorial Guinea 
receive more than $6 per person at risk of malaria but 
have per-person GDP estimates of $8137 and $19 582 
respectively, higher than most countries studied, with 
the exception of Malaysia, that have not received any 
donor assistance; substantially higher than the GDP 
estimate for Botswana, Namibia, and South Africa, which 
have not received much donor assistance for control and 
also higher than that of India and China. Despite 
evidence of biological equity, there is no correlation 
between GDP as a measure of economic equity and 
funding commitments since 2002 (r=0·051, p=0·65).
We used the needs assessment by Kiszewski and 
colleagues15 to compare per-person at-risk annualised 
donor assistance for malaria control by 2009 with 
expected per-person needs for 2010. Of 81 countries that 
have received any donor support for malaria, 21 (26%) 
had exceeded their projected yearly per-person needs 
by 2009; ten (12%) countries were within $0·5 per-person 
at risk of their projected needs and therefore seen as 
close to optimum funding; 50 (62%) countries however 
were below adequate external funding to support malaria 
prevention and disease management by 2010. Several 
countries within this group had per-person GDP 
estimates greater than $4000; however, 16 countries had 
estimates lower than $500, and ten of these countries 
were located in Africa and ﬁ ve in Asia (table). Figure 3 
shows the prioritisation of future investment by donor 
agencies to close the gap on projected country-level 
unmet needs allowing for some index of equity if national 
funding capacities were included.
Figure 2: Populations at risk of stable Plasmodium vivax or Plasmodium falciparum (PfPv PAR) versus 
cumulative funding commitments (US$) to 80 countries that had received funding by the end of 2009
Does not include two outliers: India with a huge population at risk, 758 million people, but receives only about 
$0·03 per person at risk per year, and Nigeria because it has more than 167 million people at risk of stable 
P falciparum infection, distorting the plot of funding and populations at-risk worldwide. In Nigeria funding 
increased since 2007 from $0·73–1·71 per person at risk in 2009.
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Discussion
Despite substantial increases in international donor 
assistance to malaria-endemic countries since 2007, 
worldwide commitment remains below that needed to 
mount eﬀ ective coverage of prevention and clinical 
management strategies necessary to substantially aﬀ ect 
disease burden by 2015. The RBM global business plan 
states that it needs about $4·9 billion in 2010, including 
the need to ensure rapid scale-up of campaigns for 
universal access to existing interventions in 43 sub-
Saharan African countries and India.1 These estimates 
fall within the range of the modelled predictions provided 
by Kiszewski and colleagues for average yearly funding 
between 2006 and 2015.14 Our assembly of external donor 
support to 93 malaria-endemic countries shows that, on 
an average year since 2002, $1·9 billion has been provided 
as a contribution to scaled malaria control. This funding 
has increased by 166% since 2007 but is 60% below what 
RBM has estimated is needed worldwide.
These headline ﬁ gures suggest that much more is 
needed but hide the fact that 21 countries, including 
12 in Africa, have now reached, or nearly reached, a 
predicted adequacy in donor assistance for eﬀ ective 
malaria control (ﬁ gure 3). We have deﬁ ned adequacy of 
support using  populations at risk of stable transmission 
of either P vivax or P falciparum measured against the 
predicted needs deﬁ ned for 2010 through a detailed 
costing exercise.15 Those countries that rapidly reached 
adequate levels of donor assistance have small populations 
at risk, and in many of these countries, risk is not 
distributed evenly within their borders—eg, Mauritania, 
Djibouti, Madagascar, Papua New Guinea, Sri Lanka, and 
Suriname. Measures of funding adequacy for universal 
coverage therefore imply coverage only within constrained 
areas within national borders; we cannot capture 
resources used within a country for those not at risk. Our 
metrics are useful for worldwide priority setting but 
demand more appropriate use of national-level malaria 
risk mapping and knowledge of within-country dis-
bursement to be translated into eﬀ ective use of funds.
International support for malaria control has been 
largely biologically equitable, with more funding approved 
for countries with larger populations at risk (ﬁ gure 2). 
The largest anomalies correspond to countries where 
P vivax is more ubiquitous in its distribution than 
P falciparum. This ﬁ nding highlights the neglect of this 
malaria parasite in worldwide priority setting and ﬁ nancial 
support. These anomalies are best shown by India and 
China, two countries with large populations at risk of 
P vivax malaria that need complex disease surveillance, 
clinical management, and prevention strategies, and 
where aspirations for subnational elimination might 
beneﬁ t neighbouring risk-free communities and 
neighbouring countries sharing similar ambitions such 
as Sri Lanka, Vietnam, and Thailand. India was singled 
out as a priority country within the RBM global business 
plan. Neither India nor China has very high estimates of 
GDP, or is seen as an upper-middle income country by 
the OECD (ﬁ gure 3 and table).21 These classiﬁ cations, 
however, could simply show the inadequacy of the 
GDP/GNI quotient to identify national spending 
priorities, and explain why countries with higher GDPs 
such as Gabon and Equatorial Guinea are so well funded 
through donor assistance despite large per-person 
incomes from oil revenues. India and China have space 
programmes and, at the recent meeting of the 
World Economic Forum in Davos, were seen as the 
emerging global economies of the next two decades, with 
growth and per-person income poised to surpass those of 
the USA and Europe.25 Whether such countries should 
Figure 3: Prioritisation for international donor support based on current per-person per year external malaria donor support and expected needs for 2010
Adequate funding
Close to adequate funding
Inadequate funding high GDP
Inadequate funding moderate GDP
Inadequate funding low moderate GDP
Inadequate funding low GDP
No funding
No P falciparum and P vivax stable transmission
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receive donor assistance for malaria control remains a 
point worthy of further discussion. However, if we assume 
that both India, China, and all high GDP countries shown 
in the table should support malaria-control ambitions 
from domestic resources, the resource envelope to 
support worldwide malaria control through international 
donor assistance changes substantially. Among 
70 countries prioritised by these criteria the yearly needs 
have been estimated to be $2·94 billion;15 current 
annualised donor commitments to these priority countries 
covering more than 60% of the worldwide population at 
malaria risk are $1·83 billion, 38% below what is needed 
but a gap easier to close than a 54% deﬁ cit estimated for 
all endemic countries by an adjusted needs calculation.15
Economic eligibility for donor assistance and priority 
setting for the poorest countries least able to support 
scaled malaria control from national resources needs 
further debate. As a prelude to this debate we have used a 
combination of unmet per-person at-risk funding needs 
and GDP to set some benchmarks for those countries 
that have the greatest need in 2010 but are possibly the 
least able to support these through domestic funding 
(ﬁ gure 3). At the lowest end of the GDP spectrum, 
substantial progress has been made to support the 
poorest countries in Africa, importantly by the increased 
funding made available through the President’s Malaria 
Initiative since 2005 to augment funding provided by the 
Global Fund (table). In several countries there is still a 
need to focus donor attention: these include ten high-
priority countries in Africa that represent 22% of Africa’s 
population at risk of malaria, with eight having qualiﬁ ed 
for assistance as heavily indebted poor countries 
(excluding Niger and Somalia, which were at a pre-
decision point in January 201024) and ﬁ ve high-priority 
countries in Asia that represent 11% of the at-risk 
population in this region and none of which receive relief 
as heavily indebted poor countries (table).
We assessed adequacy and equity (biological and 
economic) of external donor assistance but have not 
considered the eﬀ ectiveness of this funding in our 
investigation. However, the metrics developed here 
provide a platform for interpretation of changes in 
equitable intervention coverage with the national sample 
household surveys that form the basis for monitoring of 
RBM progress.26 Countries with adequate external donor 
assistance to scale up disease prevention and control 
should do better than their counterparts without adequate 
ﬁ nancing. In Africa, progress towards universal 
intervention access and coverage would be expected to be 
substantially faster in countries such as Rwanda, Zambia, 
and Equatorial Guinea, which have adequate predicted 
donor assistance, than in Guinea, Sierra Leone, and 
Niger, which have inadequate funding. At present, 
national sample surveys are too infrequent to allow 
examination of temporal eﬀ ectiveness of funding within 
Africa by the end of 2009. Outside Africa, comparable 
national coverage survey data are incomplete. Monitoring 
of progress towards universal intervention access must 
be considered in the context of funding made available to 
countries; inadequate funding will result in the 
incomplete coverage of interventions, which will not be 
solely a failure of national governments but a more 
collective responsibility. Conversely, adequate funding 
combined with poor coverage is an issue of accountability 
for recipient governments and partners.
We have not considered the costs per person at risk for 
a malaria elimination goal because the cost of moving 
from eﬀ ective sustained control to elimination is poorly 
understood.27 We believe that funding priorities should 
remain focused on reducing the malaria burden in high-
transmission countries.28 Our metrics are essentially 
based on intervention options for reducing endemicity to 
levels where malaria is not a major public health threat. 
These metrics have a documented eﬃ  cacy and their costs 
are generally predictable. All the countries that have not 
received any donor assistance since 2002 (ﬁ gure 1) have 
stated that they intend to eliminate malaria, with the 
exception of French Guiana.23 Other countries that 
remain poorly funded by the international donor 
community, but have nonetheless declared an elimination 
ambition, include South Africa, Namibia, Iran, the 
Philippines, Haiti, and the Dominican Republic.23 Given 
the shortfalls that exist in meeting the needs for universal 
intervention coverage for poor countries with high 
disease burdens to reach low endemic control, donors 
should work to ensure a careful approach when 
supporting diﬀ erent regional and national, less 
predictable, elimination agendas and ambitions.
We end with the inevitable plea for more money, at a 
time when developed countries face ﬁ nancial crises of 
their own. But we would like to emphasise that should 
funding commitments fall to the levels that applied 
in 2007 from those in 2009 (ﬁ gure 1) we run the risk of a 
resurgence of malaria in countries that have enjoyed the 
beneﬁ ts of this funding to provide protection from 
malaria since 2002.28 Sustained funding in these countries 
is crucial or $9·9 billion invested since 2002 will have 
been in vain.
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